TrumpRx: US President Donald Trump had announced this week that his administration plans to roll out a new website, called TrumpRx, which will allow Americans to purchase prescription medications from pharmaceutical companies at discounted rates. In a major step to address rising drug costs, the Trump administration also unveiled agreements with Eli Lilly and Novo Nordisk to reduce prices for popular GLP-1 medications like Ozempic, Wegovy, and Zepbound. These deals, part of the TrumpRx initiative, are expected to make the drugs more affordable for Medicare, Medicaid, and direct consumers starting in 2026.Trump Annoucement Today: What Is TrumpRx?TrumpRx is an online platform designed to let consumers buy prescription medicines directly from the manufacturers, bypassing insurance intermediaries. The website is scheduled to launch in early 2026. Users will be able to search for the specific drug they need and be directed to the drug’s manufacturer, according to USA Today. The platform will offer prices closer to what national health services pay in other countries, following the principle of “most favoured nation” pricing. Medicaid beneficiaries—federal insurance for low-income adults and children—will also have access to the platform.TrumpRx: Will The New Website Slash Prescription Drug Prices?The website is part of a broader effort by Trump to curb high prescription drug costs in the US. In July, he sent a letter to the CEOs of 17 pharmaceutical companies demanding lower prices.In the letter, he outlined several key points:Manufacturers must provide MFN (most favoured nation) prices to all Medicaid patients.Companies must ensure that new drugs are not sold at lower prices in other developed nations than in the US.Manufacturers will have an option to sell directly to patients, cutting out middlemen, but prices cannot exceed the lowest rates in other developed countries.Trade policies will be leveraged to support higher international pricing, with any additional revenue abroad reinvested to reduce costs for American consumers and taxpayers.TrumpRx: Who Will Benefit Most From This Platform?Anyone looking to buy prescription drugs directly from manufacturers, rather than through insurance, could benefit. A 2024 US Census Bureau report noted that 8% of Americans (about 26 million people) lacked health insurance in 2023, meaning they could significantly benefit from lower prices. Medicaid may also benefit, as its deal with Pfizer offers better pricing terms. Details about how this part of the program will work are not fully clear yet. Since most Americans rely on insurance for healthcare, experts believe initial adoption of the site may be limited.TrumpRx: Trump Announces Deal With Drugmakers to Lower Cost of Weight-Loss DrugsOn Thursday, President Trump announced deals with Novo Nordisk and Eli Lilly to cut costs for the lowest doses of their popular weight-loss drugs, lowering barriers for new patients seeking treatment. Beyond government programs, the same GLP-1 drugs will be available directly to consumers via TrumpRx.gov, launching in January 2026.The starting doses of injectable Wegovy and Zepbound will cost $350 per month but are expected to trend down to $245 over two years. Oral versions, including Novo Nordisk’s upcoming semaglutide pill and Eli Lilly’s orforglipron, will start at $149 per month once approved.
Email
Google
Facebook Email Google Facebook